Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 8/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.61 |
| ▸ | CYSLTR1 | Q9Y271 | 10/20 | 0.59 |
| ▸ | CYSLTR2 | Q9NS75 | 9/20 | 0.59 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.57 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.57 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8800199 | 0.82 | ALOX5 (0.72) | ALOX5CYSLTR1CYSLTR2FFAR1AKR1B1 | |
| SCHEMBL1419872 | 0.80 | FFAR1 (0.77) | ALOX5CYSLTR1CYSLTR2FFAR1AKR1B1 | |
| SCHEMBL1419751 | 0.80 | CYSLTR1 (0.73) | ALOX5CYSLTR1CYSLTR2FFAR1AKR1B1 | |
| SCHEMBL8902567 | 0.79 | ALOX5 (0.72) | ALOX5CYSLTR1CYSLTR2FFAR1AKR1B1 | |
| SCHEMBL1419915 | 0.79 | ALOX5 (0.72) | ALOX5CYSLTR1CYSLTR2FFAR1AKR1B1 | |
| SCHEMBL10411541 | 0.79 | FFAR1 (0.67) | ALOX5CYSLTR1CYSLTR2FFAR1AKR1B1 | |
| SCHEMBL8965425 | 0.78 | CYSLTR1 (0.64) | ALOX5HDAC6CYSLTR1CYSLTR2FFAR1 | |
| SCHEMBL8870875 | 0.78 | ALOX5 (0.61) | ALOX5HDAC6CYSLTR1CYSLTR2FFAR1 | |
| Bicarbonate SCHEMBL9374712 | 0.77 | CYSLTR1 (0.72) | ALOX5HDAC6CYSLTR1CYSLTR2FFAR1 | |
| SCHEMBL9137219 | 0.77 | GPBAR1 (0.67) | ALOX5HDAC6CYSLTR1CYSLTR2FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9617597-B2 | Genetic susceptibility variants associated with cardiovascular disease | DECODE GENETICS EHF (IS) | 2017-04-11 | — | — | US | disclosed |
| EP-2471954-B1 | Genetic susceptibility variants associated with cardiovascular disease | DECODE GENETICS EHF (IS) | 2016-08-24 | — | — | EP | disclosed |
| US-20120208709-A1 | GENETIC SUSCEPTIBILITY VARIANTS ASSOCIATED WITH CARDIOVASCULAR DISEASE | DECODE GENETICS EHF. (IS) | 2012-08-16 | — | — | US | disclosed |
| EP-2471954-A1 | Genetic susceptibility variants associated with cardiovascular disease | Decode Genetics EHF (IS) | 2012-07-04 | — | — | EP | disclosed |
| US-8158362-B2 | Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype | DECODE GENETICS EHF. (IS) | 2012-04-17 | — | — | US | disclosed |
| US-20100216863-A1 | Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment | DECODE GENETICS EHF. (IS) | 2010-08-26 | — | — | US | disclosed |
| US-20100120045-A1 | GENETIC VARIANTS USEFUL FOR RISK ASSESSMENTS OF CORONARY ARTERY DISEASE AND MYOCARDIAL INFARCTION | DECODE GENETICS EHF (IS) | 2010-05-13 | — | — | US | disclosed |
| US-20100068705-A1 | GENETIC SUSCEPTIBILITY VARIANTS ASSOCIATED WITH CARDIOVASCULAR DISEASE | DECODE GENETICS EHF (IS) | 2010-03-18 | — | — | US | disclosed |
| US-20070280917-A1 | Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment | DECODE GENETICS, INC. (IS) | 2007-12-06 | — | — | US | disclosed |
| US-20060019269-A1 | Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment | DECODE GENETICS, INC. (IE) | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120045-A1 | GENETIC VARIANTS USEFUL FOR RISK ASSESSMENTS OF CORONARY ARTERY DISEASE AND MYOCARDIAL INFARCTION | TNNI3, TSG101, ALDH1B1 | ALOX5 728/4885HDAC6 3918/4885CYSLTR1 285/4885 |
| US-20100216863-A1 | Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment | ALOX15B, ALOX15, ALOX5 | ALOX5 3/4885HDAC6 4504/4885CYSLTR1 48/4885 |
| US-20070280917-A1 | Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment | ALOX15B, ALOX15, ALOX5 | ALOX5 3/4885HDAC6 4504/4885CYSLTR1 48/4885 |
| US-20060019269-A1 | Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment | PLAAT3, PLAAT2, PLA2G7 | ALOX5 13/4885HDAC6 4187/4885CYSLTR1 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.